Please note: This review reflects information we gathered on the date it was researched and may now be out of date. Providers frequently change their pricing, plans, medications, and policies. Any ratings, reviews, and customer feedback are gathered from publicly available online sources and may have since changed or no longer be accurate. Always do your own research and confirm the latest details directly with the provider before making any decision.
Intellectia.AI Review: 200% Backtested, Zero Risk Disclosure
Intellectia.AI is an AI stock analysis platform that generates trade ideas, publishes weekly stock picks, offers copy-trading signals and connects directly to brokerage accounts to place orders. It advertises an over 200% annualised return, proven via backtesting. It has nothing to do with GLP-1 medication and we say so plainly — it reached us through an affiliate queue. We have reviewed it anyway, because across its homepage, pricing page, terms of service and privacy policy we could not find the phrase past performance, or risk of loss, or not investment advice, even once.
Before anything else: what we searched for and did not find
Across four pages — the homepage, the pricing page, a 26,018-character terms of service and a 32,113-character privacy policy — these phrases each returned zero matches: past performance, not investment advice, investment advice, risk of loss, lose money, loss of principal, hypothetical, informational purposes, educational purposes. Searched with word boundaries: SEC, RIA, FINRA, registered investment, broker-dealer — also zero.
Past performance is not indicative of future results is the most routine sentence in consumer finance. It appears on the marketing of virtually every fund, brokerage and newsletter in the United States. We are not lawyers and we are not asserting that any rule has been broken. We are telling you exactly what we looked for, and that we did not find it, next to an advertised 200% return.
Our Verdict
Intellectia.AI · intellectia.ai · free tier to $499.99/year
“Proven, via backtesting” is not a thing that can be proven
The homepage says twice that the AI Stock Picker strategy has proven, via backtesting, to achieve an over 200% annualised return. A backtest is a simulation of how rules would have performed on data that already exists. It proves nothing about tomorrow. Backtests overstate returns for well-understood reasons: strategies get tuned until they fit past data, failed companies drop out of historical indices, information leaks backwards into the simulation, and trading costs and slippage are usually ignored.
It does not just advise. It trades.
The platform describes connecting brokers including Webull and Alpaca, executing market or limit orders without leaving the dashboard, and a SwingMax Copy Trade feature that syncs and copies real-time AI signals automatically, pausing during what it calls high-risk conditions to protect your capital. Research software that is wrong costs you an afternoon. Signal software wired into a live brokerage account that is wrong costs you money, automatically, while you are not watching.
A testimonial claiming 22.6% a month
Displayed on the homepage: a user reporting returns of 22.6% per month, up from 7.9% before. Compounded, that is well over a thousand per cent annually — a rate no institution in the world sustains. Alongside it: 15% added to my win rate, 80% time saved, and 90% cheaper than traditional financial advisors. Unverified individual returns are the weakest form of evidence in finance, and these are presented with no counterweight of any kind.
A $10,000 capital suggestion, and real prices
The SwingMax portfolio product is described as ideal for investors with at least $10,000 in capital. Subscriptions run to $499.99 a year for that product, discounted from a stated $799.99, with the whales tracker at $319.95 a year and the Backtest Playground at $29.99 a month. So the proposition is a several-hundred-dollar annual subscription plus a five-figure capital commitment, sold on a backtested figure.
What it does get right
There is a genuinely free forever tier and a $1 trial, so nobody has to pay to find out whether they like the interface. Pricing is published openly across five named tiers rather than hidden behind a sales call. The underlying feature set — screeners, earnings calendars, technical analysis, institutional and congressional holdings tracking — is real functionality that other platforms also sell, and some of it is genuinely useful for research.
Our Top Recommended Provider: CoreAge Rx
After reviewing dozens of GLP-1 telehealth providers, CoreAge Rx is the one we recommend most. CoreAge Rx is one of our partners — read on for why we recommend them:
Flat-Rate Pricing
Same cost at every dose level — no price jumps as you titrate up.
Verified Pharmacies
US-licensed physicians and NABP-verified 503A compounding pharmacies you can trust.
Everything Included
Medication, supplies, free shipping, and ongoing clinical support — no hidden fees.
Active Community of Members
Ask questions, share progress, and get answers from other patients on the same journey — alongside ongoing clinical support from your care team.
0
Mentions of “past performance” across 4 pages
0
Mentions of risk of loss, or losing money
200%+
Annualised return advertised, from a backtest
$10,000
Suggested minimum capital for SwingMax
Why a backtest is not a result
1. The four ways historical simulations flatter a strategy
Backtesting is a legitimate research tool. It becomes marketing when the output is presented as proof. Four well-documented effects push simulated returns above what the same rules deliver in the future, and all four are invisible in a headline number.
- Overfitting. Run enough parameter combinations against history and some will look spectacular by chance. The more variations tested, the more certain it becomes that the winner is fitted to noise rather than signal.
- Survivorship bias. Historical stock universes often exclude companies that went bankrupt or were delisted. A strategy backtested on today's surviving companies has been quietly told which firms not to worry about.
- Look-ahead bias. If the simulation uses data that was not actually available at the moment of the simulated trade — restated earnings, later-revised figures, index membership known only in hindsight — it is trading with information from the future.
- Costs and slippage. Commissions, spreads, and the price impact of actually buying are frequently omitted. On a weekly-rebalanced ten-stock portfolio, which is what the AI Stock Picker describes, those costs are not a rounding error.
A 200% annualised return would place a strategy far above the long-run record of essentially every professional investor who has ever operated. The reasonable inference is not that the model is extraordinary. It is that the simulation has one or more of the problems above, and no information on the page lets a reader check which.
2. The missing sentence, and why it is standard
Past performance is not indicative of future results appears on fund factsheets, brokerage advertising, newsletters and trading platforms across the industry. It is there because regulators, litigation and hard experience have all established the same thing: consumers systematically read historical returns as forecasts. Where the performance shown is hypothetical or backtested rather than actually achieved, the convention is stronger still — such figures are normally labelled hypothetical and accompanied by an explanation of their limitations.
We searched for all of it. Past performance: zero. Hypothetical: zero. Risk of loss, lose money, loss of principal: zero. Not investment advice: zero. Informational purposes and educational purposes, the usual framing for research tools that wish to stay clear of advice: zero. Those searches covered a terms of service of over 26,000 characters and a privacy policy of over 32,000, so this is not a case of a short site with little text.
We also checked, with word boundaries to avoid false matches, for SEC, RIA, FINRA, registered investment and broker-dealer. All zero. We make no claim about whether registration is legally required here — that turns on how the service is structured and on facts we cannot see. What we can say is that a platform issuing trade signals and executing orders through connected brokerage accounts tells the reader nothing at all about its regulatory position.
3. When the model is wrong and the account is connected
There is a meaningful difference between software that tells you what it thinks and software that acts. Intellectia describes both: a one-minute setup to link Webull, Alpaca and others, execution of market and limit orders from inside the research dashboard, and a copy-trade product that syncs real-time AI signals automatically so that, in its words, no manual analysis is required.
It also claims the system pauses trading during high-risk conditions to protect your capital. That is a substantial promise about behaviour in exactly the conditions where models fail most often — regime changes, gaps, liquidity droughts. No detail is offered about how high-risk conditions are detected or what the pause does to open positions.
Add the language-model dimension and the risk compounds. Systems built on large language models produce fluent, confident text whether the underlying number is right or invented; a hallucinated earnings figure or ratio reads exactly like a correct one. Anything an AI asserts about a company should be verified against a filing before money moves — which erodes the time-saving that is the product's main practical selling point.
4. The one connection to this site, and it is a cautionary one
Readers of a GLP-1 site have watched a live demonstration of why thematic momentum trading is hard. The obesity drug story has been one of the defining market narratives of the decade, producing enormous gains for the companies involved — and then severe drawdowns when trial readouts disappointed and competitive dynamics shifted. Investors who arrived late, on the strength of a trend that had already run, learned what that costs.
That is exactly the pattern a momentum-driven weekly picker is built to chase. A model selecting the top ten stocks each Monday on recent strength will load into precisely the themes that have already moved, and will be holding them when the readout misses. If you have followed the GLP-1 sector as a patient, you have front-row evidence for why the 200% number deserves scepticism rather than enthusiasm.
What it costs
| Product | Price | Notes |
|---|---|---|
| Free tier | $0 forever | Genuine, and the only version we would suggest touching |
| Trial | $1 | Explore before subscribing |
| Backtest Playground | $29.99/mo or $359.99/yr | 30–40 runs a month |
| Whales tracker | $199.95/6mo or $319.95/yr | Institutional and congressional holdings |
| SwingMax Portfolio | $499.99/yr, from a stated $799.99 | Plus a suggested $10,000 in capital |
In its favour
- A genuinely free forever tier, so you can assess it without paying.
- A $1 trial, and pricing published openly across five named tiers.
- Real underlying functionality: screeners, earnings calendars, technical analysis, institutional and congressional holdings tracking.
- The Backtest Playground is honestly named — it lets you test your own ideas rather than only buy theirs.
- Broker integrations are with recognised platforms rather than an in-house wallet.
- No hidden sales call required to see prices.
Against it
- Advertises an over 200% annualised return as proven via backtesting, which is not something a backtest can establish.
- Zero occurrences of past performance, hypothetical, risk of loss, lose money or loss of principal across four pages.
- Zero occurrences of not investment advice, informational purposes or educational purposes.
- Zero word-boundary matches for SEC, RIA, FINRA, registered investment or broker-dealer — no stated regulatory position.
- A homepage testimonial claiming 22.6% monthly returns, displayed without qualification.
- Copy trading and direct order execution turn a wrong model into automatic losses.
- Claims to pause trading in high-risk conditions to protect capital, with no explanation of how.
- Suggests a $10,000 minimum capital on top of a $499.99 annual subscription.
- AI-generated financial analysis can state fabricated figures fluently, requiring verification that negates the time saved.
Our verdict: 1.8 out of 5
A capable research platform wrapped in performance marketing that would be unremarkable on a supplement bottle and is alarming on something wired into a brokerage account.
The software underneath is probably fine. Screeners, earnings calendars, technical charting and institutional holdings tracking are standard tools, other people sell them, and a free tier lets you judge the interface at no cost. If Intellectia sold only that, this would be a mild review about whether the AI layer adds enough to justify the price.
It does not sell only that. It sells a weekly ten-stock picker advertised at over 200% annualised, a copy-trading product that executes automatically, and direct order routing into live brokerage accounts — and it does so without, so far as we can find, a single sentence anywhere acknowledging that investments can lose money. We searched a homepage, a pricing page, a 26,000-character terms of service and a 32,000-character privacy policy. Past performance: zero. Risk of loss: zero. Hypothetical: zero. Not investment advice: zero.
We are not lawyers and we are not alleging a breach of any rule; that would require knowing how the service is structured. What we can say as reviewers is that the omission is conspicuous. The sentence about past performance exists on almost every financial product sold in America precisely because people read historical numbers as promises. Presenting a backtested 200% figure and a testimonial claiming 22.6% a month, with no counterweight at all, leaves a reader with no cue to be careful.
And the number itself should be the tell. A strategy compounding at over 200% a year would turn ten thousand dollars into more than a million inside five years. Nobody in the history of professional investing has sustained that. The likeliest explanations are the ordinary ones — overfitting, survivorship bias, look-ahead bias, ignored trading costs — and the page gives you nothing with which to check.
So: 1.8. If you want the screeners, take the free tier and pay nothing. Do not connect a brokerage account to a signal service advertising returns it describes as proven by simulation. Do not treat AI-generated commentary about a company as accurate without checking the filing. And if the GLP-1 sector taught you anything as a patient watching those companies soar and then fall hard on a disappointing readout, apply it here: the strategies that look most impressive in the rear-view mirror are the ones most likely to have been fitted to it.
Frequently asked questions
Why is a GLP-1 site reviewing a stock trading app?
It came through our affiliate queue and there is no health angle. We are reviewing it as a consumer purchase because it is the kind of product where the marketing and the risk are furthest apart, and because there is one genuinely apt connection: GLP-1 drugs have been among the most dramatic market stories of the decade, producing enormous gains and then severe drawdowns when trial results disappointed. If you want an illustration of why an AI momentum picker on a hot theme is dangerous, this audience has lived through one.
What is the 200% claim?
The homepage states, twice, that the AI Stock Picker strategy has proven, via backtesting, to achieve an over 200% annualised return. Backtesting is a simulation of how a strategy would have performed on historical data. It cannot prove anything about future returns, and the phrase proven via backtesting is close to a contradiction in terms. Backtests systematically flatter strategies through overfitting to past data, survivorship bias in the stock universe, look-ahead bias, and the omission of trading costs and slippage.
What disclaimers does it carry?
None that we could find. We searched the homepage, the pricing page, a 26,000-character terms of service and a 32,000-character privacy policy for the phrases past performance, not investment advice, investment advice, risk of loss, lose money, loss of principal, hypothetical, informational purposes and educational purposes. Every one returned zero matches on every page. Past performance is not indicative of future results is the most standard sentence in all of consumer finance, and it does not appear.
Is it a registered investment adviser?
We found no claim either way. Searching all four pages with word boundaries for SEC, RIA, FINRA, registered investment and broker-dealer returned zero matches. We are not asserting that registration is required — that depends on facts we cannot assess from outside. We are reporting that a service generating trade signals, offering copy trading and executing orders through linked brokerage accounts says nothing anywhere about its regulatory status.
Does it actually place trades?
Yes, if you connect it. The site describes linking brokers including Webull and Alpaca, executing market or limit orders without leaving the dashboard, and a SwingMax Copy Trade feature that syncs and copies real-time AI signals automatically. That is materially different from research software. Once signals reach a live brokerage account, the gap between a bad model and real money disappears.
What does it cost?
There is a genuinely free tier and a $1 trial, which we credit. Paid products run from $29.99 a month for the Backtest Playground, through $199.95 for six months or $319.95 a year for the whales tracker, up to the SwingMax Portfolio at $499.99 a year, discounted from a stated $799.99. Tiers are labelled Free, Basic, Pro, Max and Expert. The SwingMax description says it is ideal for investors with at least $10,000 in capital.
What about the testimonial claiming 22.6% a month?
Take it as a warning rather than a selling point. A homepage testimonial states a return of 22.6% per month, up from 7.9% before. Compounded, 22.6% monthly is well over a thousand per cent a year — a rate that would make the individual concerned one of the most successful investors in recorded history within a few years. Testimonials are not evidence, unverified individual returns least of all, and displaying that figure without any accompanying risk statement is the clearest signal on the page.
Can an AI model just make things up about a stock?
Yes, and it is a real risk with any language-model-driven analysis. These systems generate fluent text whether or not the underlying figure is correct, and a confidently stated but fabricated earnings number or ratio reads exactly like an accurate one. Any AI-generated financial claim should be checked against a filing or a primary data source before you act on it — which somewhat undercuts the time-saving proposition.
If you look at all, look at the free tier
We are not recommending this product, and we are certainly not recommending connecting a brokerage account to it. There is a free forever tier and a $1 trial if you want to see the research tools. The link below pays us 24% — up to about $120 on the annual plan — which is the money we are turning down by writing this.
View Intellectia.AI (affiliate link)Pricing, claims and page content verified 11 August 2026 and subject to change.
Compare Other GLP-1 Providers
See how other telehealth providers stack up.
LifeMD
Top RatedPublicly traded telehealth company with comprehensive health platform and competitive pricing
Read Review →JumpstartMD
Comprehensive ProgramMedically supervised program with obesity medicine physicians, dietitians, and in-person options
Read Review →Mochi Health
Obesity Medicine SpecialistsBoard-certified obesity medicine specialists with both brand-name and compounded GLP-1 options
Read Review →CoreAge Rx
#1 RecommendedFlat-rate pricing for compounded semaglutide and tirzepatide with NABP-verified pharmacies
Read Review →Henry Meds
Top RatedWell-established telehealth platform with fast physician reviews and competitive pricing
Read Review →Boston Medical Group
Top RatedEstablished telehealth provider with physician oversight and transparent pricing
Read Review →Scope, financial and legal disclaimer
This is a consumer review of a software product, published on a health site because it reached us through an affiliate queue. It contains no medical content and is not medical advice. It is emphatically not investment advice, not a recommendation to buy, sell or hold any security, and not a solicitation. We are not investment advisers, brokers or lawyers. Investing carries risk including the loss of principal, and past performance — real or simulated — does not indicate future results. Backtested and hypothetical performance figures have inherent limitations and do not represent actual trading. Anyone considering an investment product, an automated trading service, or linking a brokerage account to a third party should consult a qualified, appropriately registered financial professional first. Our statements about disclosure and registration describe what we did and did not find in published materials on the date given; they are not legal conclusions about this company's obligations or compliance.
Sources · date reviewed: 11 August 2026
- intellectia.ai homepage — retrieved 11 August 2026. Source for the statement, appearing twice, that the AI Stock Picker strategy has proven, via backtesting, to achieve an over 200% annualised return; for the SwingMax Copy Trade description including syncing and copying real-time AI signals and pausing trading during high-risk conditions to protect your capital; for broker connection to Webull, Alpaca and others with market and limit order execution; and for the displayed testimonials including 22.6% monthly returns, 15% added win rate, 80% time saved and 90% cheaper than traditional financial advisors.
- intellectia.ai/pricing — retrieved 11 August 2026. Source for the $0 forever tier, the $1 trial, Backtest Playground at $29.99 monthly or $359.99 annually, whales tracker at $199.95 for six months or $319.95 annually, SwingMax Portfolio at $499.99 annually from a stated $799.99, the Free/Basic/Pro/Max/Expert tier names, and the statement that SwingMax is ideal for investors with at least $10,000 in capital.
- intellectia.ai/terms-of-service (26,018 characters) and intellectia.ai/privacy (32,113 characters) — both retrieved 11 August 2026 and searched in full.
- Keyword audit across all four pages, conducted 11 August 2026. Zero matches on every page for: past performance; not investment advice; investment advice; risk of loss; lose money; loss of principal; hypothetical; informational purposes; educational purposes. Zero word-boundary matches on every page for: SEC; RIA; FINRA; registered investment; broker-dealer. Apparent matches for SEC and RIA in an initial substring search were false positives inside other words and were excluded after re-testing with word boundaries.
- Backtesting limitations described — overfitting, survivorship bias, look-ahead bias, and omission of transaction costs and slippage — are standard, long-documented issues in quantitative finance, not specific findings about this company's methodology, which is not published.
- Katalys offer listing #1440, retrieved 11 August 2026 — 24.00% commission, United States targeting, Finance vertical, sub-network Impact, permitted channel Content only.
We did not create an account, take the $1 trial, subscribe, connect a brokerage account or evaluate the accuracy of any signal or analysis the platform produces. Our findings concern the company's published marketing and legal documents only. We did not contact the company before publishing, and we would update this page if risk and performance disclosures were added.
Affiliate disclosure
GLP1Drugs.org earns a 24% commission on subscriptions referred through the links on this page — up to roughly $120 on the $499.99 annual plan. We have rated Intellectia.AI 1.8 out of 5, advised readers not to subscribe and not to connect a brokerage account, and led the review with the disclosures we could not find. No company reviewed here sees or approves our copy before publication.